Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).
Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
Vifor Pharma has set up this community to share with you news about the company and the current open positions. Sensitive topics, such as discussions about products or treatment options should be addressed privately with your physician. If you are concerned with an adverse event of a drug or a complaint regarding a product, please directly email safety@viforpharma.com or call +41 79 788 03 09.
Community Guidelines: https://bit.ly/2P5Uvzj
As part of our commitment to you we will endeavour to ensure that the content on this page is positive and respectful. In doing so we ask that you respect our LinkedIn page guidelines which you find here: https://bit.ly/2P5Uvzj
Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
Vifor Pharma has set up this community to share with you news about the company and the current open positions. Sensitive topics, such as discussions about products or treatment options should be addressed privately with your physician. If you are concerned with an adverse event of a drug or a complaint regarding a product, please directly email safety@viforpharma.com or call +41 79 788 03 09.
Community Guidelines: https://bit.ly/2P5Uvzj
As part of our commitment to you we will endeavour to ensure that the content on this page is positive and respectful. In doing so we ask that you respect our LinkedIn page guidelines which you find here: https://bit.ly/2P5Uvzj
Location: Switzerland, St. Gallen
Employees: 1001-5000
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Ally Bridg... | ally-bridg... |
| - | New Leaf V... | nlvpartner... |
Mentions in press and media 23
| Date | Title | Description |
| 25.08.2026 | Three Swiss biotechs promote from within | Lausanne-based Avrion Therapeutics, an EPFL spin-off founded in 2020, has appointed co-founder Maximilien Murone as interim Chief Executive Officer in June. He succeeds Harald Petry, who has led the preclinical-stage biotech since 2022 and... |
| 26.02.2026 | Slate Medicines Secures $130M to Advance Migraine Prevention | Slate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headach... |
| 24.02.2026 | Slate Medicines: $130 Million Series A Raised To Advance Anti-PACAP Migraine Therapies | Slate Medicines, a privately held biotech company developing next-generation therapeutics for headache disorders, has launched with the close of a $130 million Series A financing and the in-licensing of SLTE-1009, an anti-PACAP monoclonal a... |
| 26.09.2025 | CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy | FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX... |
| 23.05.2025 | England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy | First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT... |
| 29.04.2025 | CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy | European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation from Committee for Medicinal Products for ... |
| 17.10.2024 | CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy | Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeuti... |
| 24.09.2024 | Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia | Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients 1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan ST. GALLEN, Switzerland, Sept. 24, 2024 /... |
| 24.04.2024 | CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy | First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ... |
| 28.03.2024 | Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients | ST. GALLEN, SWITZERLAND, March 28, 2024 /PRNewswire/ -- CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatm... |
Show more